|
A prognostic model based on computed tomography radiomics to evaluate response of immunotherapy in non-small cell lung cancer using clinical data
|
D. Wang   , X. Wang , Z. Wang , Y. Xu |
| Department of Thoracic Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, 200000, China , xyd927927@163.com |
|
|
Abstract: (643 Views) |
Background: This study aimed to develop and validate a computed tomography (CT) radiomics–based model for predicting immunotherapy response and prognosis in patients with advanced non-small cell lung cancer (NSCLC). Materials and Methods: A total of 117 patients with advanced NSCLC treated with PD-1/PD-L1 immune checkpoint inhibitors were retrospectively enrolled from two centers. Baseline CT scans obtained before immunotherapy and follow-up CT scans acquired 6–8 weeks after treatment initiation were analyzed. Tumor lesions were manually segmented, and radiomics features were extracted. Two support vector machine–based models were constructed: a pre-treatment CT (pre-CT) model and a delta-CT model derived from changes in radiomics features before and after immunotherapy. Model performance for predicting immunotherapy response, defined according to RECIST 1.1 criteria, was evaluated using receiver operating characteristic (ROC) analysis. Kaplan–Meier survival analysis was performed to assess the prognostic value of radiomics scores. Results: In the training cohort, the pre-CT and delta-CT models achieved area under the ROC curve (AUC) values of 0.825 and 0.844, respectively. In the validation cohort, the delta-CT model demonstrated superior predictive performance (AUC: 0.795) compared with the pre-CT model (AUC: 0.686). Subgroup analysis showed that the delta-CT model performed well in adenocarcinoma patients, whereas the pre-CT model showed better discrimination in squamous cell carcinoma patients. Higher delta-CT radiomics scores were significantly associated with poorer OS and PFS. Conclusion: CT radiomics models, particularly those based on longitudinal changes after immunotherapy, can effectively predict immunotherapy response and prognosis in advanced NSCLC, providing a non-invasive tool to support clinical decision-making. |
|
| Keywords: Non-small-cell lung cancer, immunotherapy, CT radiomics, therapeutic effect, prognosis. |
|
|
Full-Text [PDF 1240 kb]
(257 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. 1. Desai A and Peters S (2023) Immunotherapy-based combinations in metastatic NSCLC. Cancer Treatment Reviews, 116: 102545. [ DOI:10.1016/j.ctrv.2023.102545] 2. West HJ and Kim JY (2024) Rapid advances in resectable non-small cell lung cancer: A narrative review. JAMA Oncology, 10(2): 249-55. [ DOI:10.1001/jamaoncol.2023.5276] 3. Sorin M, Prosty C, Ghaleb L, Nie K, Katergi K, Shahzad MH, et al. (2024) Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis. JAMA Oncology, 10(5): 621-33. [ DOI:10.1001/jamaoncol.2024.0057] 4. Alduais Y, Zhang H, Fan F, Chen J, Chen B (2023) Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine, 102(8): e32899. [ DOI:10.1097/MD.0000000000032899] 5. Deshpand R, Chandra M, Rauthan A (2022) Evolving trends in lung cancer: Epidemiology, diagnosis, and management. Indian Journal of Cancer, 59(Supplement): S90-s105. [ DOI:10.4103/ijc.IJC_52_21] 6. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. (2023) Lung cancer immunotherapy: progress, pitfalls, and promises. Molecular Cancer, 22(1): 40. [ DOI:10.1186/s12943-023-01740-y] 7. Caii W, Wu X, Guo K, Chen Y, Shi Y, Chen J (2024) Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients. Cancer Immunology, Immunotherapy: CII, 73(8): 153. [ DOI:10.1007/s00262-024-03724-3] 8. Hu Q, Li K, Yang C, Wang Y, Huang R, Gu M, et al. (2023) The role of artificial intelligence based on PET/CT radiomics in NSCLC: Disease management, opportunities, and challenges. Frontiers in Oncology, 13: 1133164. [ DOI:10.3389/fonc.2023.1133164] 9. Zheng J, Xu S, Wang G, Shi Y (2024) Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer. Front Immunol, 15: 1434171. [ DOI:10.3389/fimmu.2024.1434171] 10. Felfli M, Liu Y, Zerka F, Voyton C, Thinnes A, Jacques S, et al. (2023) Systematic review, meta-analysis and radiomics quality score assessment of ct radiomics-based models predicting tumor egfr mutation status in patients with non-small-cell lung cancer. International Journal of Molecular Sciences, 24(14). [ DOI:10.3390/ijms241411433] 11. Owens C, Hindocha S, Lee R, Millard T, Sharma B (2023) The lung cancers: staging and response, CT, (18)F-FDG PET/CT, MRI, DWI: review and new perspectives. The British Journal of Radiology, 96(1148): 20220339. [ DOI:10.1259/bjr.20220339] 12. Wu L, Lou X, Kong N, Xu M, Gao C (2023) Can quantitative peritumoral CT radiomics features predict the prognosis of patients with non-small cell lung cancer? A systematic review. European Radiology, 33(3): 2105-17. [ DOI:10.1007/s00330-022-09174-8] 13. Wu M, Zhang Y, Zhang J, Zhang Y, Wang Y, Chen F, et al. (2021) A combined-radiomics approach of CT images to predict response to anti-PD-1 immunotherapy in NSCLC: A Retrospective multicenter study. Front Oncol, 11: 688679. [ DOI:10.3389/fonc.2021.688679] 14. Chen M, Lu H, Copley SJ, Han Y, Logan A, Viola P, et al. (2023) A novel radiogenomics biomarker for predicting treatment response and pneumotoxicity from programmed cell death protein or ligand-1 inhibition immunotherapy in NSCLC. Official publication of the International Association for the Study of Lung Cancer: Journal of Thoracic Oncology, 18(6): 718-30. [ DOI:10.1016/j.jtho.2023.01.089] 15. Gong J, Bao X, Wang T, Liu J, Peng W, Shi J, et al. (2022) A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer. Oncoimmunology, 11(1): 2028962. [ DOI:10.1080/2162402X.2022.2028962] 16. Lazzari C, Spagnolo CC, Ciappina G, Di Pietro M, Squeri A, Passalacqua MI, et al. (2023) Immunotherapy in early-stage non-small cell lung cancer (NSCLC): Current evidence and perspectives. Current Oncology (Toronto, Ont), 30(4): 3684-96. [ DOI:10.3390/curroncol30040280] 17. Jonna S and Subramaniam DS (2019) Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discovery Medicine, 27(148): 167-70. 18. Pan F, Feng L, Liu B, Hu Y, Wang Q (2023) Application of radiomics in diagnosis and treatment of lung cancer. Frontiers in Pharmacology, 14: 1295511. [ DOI:10.3389/fphar.2023.1295511] 19. Manafi-Farid R, Askari E, Shiri I, Pirich C, Asadi M, Khateri M, et al. (2022) [(18)F]FDG-PET/CT radiomics and artificial intelligence in lung cancer: Technical aspects and potential clinical applications. Seminars in Nuclear Medicine, 52(6): 759-80. [ DOI:10.1053/j.semnuclmed.2022.04.004] 20. Tong H, Sun J, Fang J, Zhang M, Liu H, Xia R, et al. (2022) A machine learning model based on PET/CT radiomics and clinical characteristics predicts tumor immune profiles in non-small cell lung cancer: A retrospective multicohort study. Frontiers in Immunology, 13: 859323. [ DOI:10.3389/fimmu.2022.859323] 21. Lin X, Liu Z, Zhou K, Li Y, Huang G, Zhang H, et al. (2025) Intratumoral and peritumoral PET/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC. British Journal of Cancer, 132(6): 558-68. [ DOI:10.1038/s41416-025-02948-z] 22. Jin H, Wang Y, Li X, Yang Y, Qi R (2024) Radiomics nomogram for predicting chemo-immunotherapy efficiency in advanced non-small cell lung cancer. Scientific Reports, 14(1): 20788. [ DOI:10.1038/s41598-024-63415-y] 23. Farina B, Guerra ADR, Bermejo-Peláez D, Miras CP, Peral AA, Madueño GG, et al. (2023) Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients. Journal of Translational Medicine, 21(1):174. [ DOI:10.1186/s12967-023-04004-x] 24. Lei Y, Fan W, Liu B, Liao Y, Liu C, Xue S, et al. (2025) Integrated radiomics and immune infiltration analysis to decipher immunotherapy efficacy in lung adenocarcinoma. Quantitative Imaging in Medicine and Surgery, 15(4): 3123-47. [ DOI:10.21037/qims-24-130] 25. Zhang Y, Yang Y, Ma Y, Liu Y, Ye Z (2024) Development and validation of an interpretable radiomic signature for preoperative estimation of tumor mutational burden in lung adenocarcinoma. Frontiers in Genetics, 15: 1367434. [ DOI:10.3389/fgene.2024.1367434] 26. Mu W, Tunali I, Gray JE, Qi J, Schabath MB, Gillies RJ (2020) Radiomics of (18)F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 47(5): 1168-82. [ DOI:10.1007/s00259-019-04625-9] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Wang D, Wang X, Wang Z, Xu Y. A prognostic model based on computed tomography radiomics to evaluate response of immunotherapy in non-small cell lung cancer using clinical data. Int J Radiat Res 2026; 24 (3) :577-584 URL: http://ijrr.com/article-1-7165-en.html
|
